David M. Vail
Colorado State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David M. Vail.
Cancer Investigation | 2000
David M. Vail; E. Gregory MacEwen
Spontaneous tumors in companion animals (dog and cat) offer a unique opportunity as models for human cancer biology and translational cancer therapeutics. The relatively high incidence of some cancers, similar biologic behavior, large body size, comparable responses to cytotoxic agents, and shorter overall lifespan are the factors that contribute to the advantages of the companion animal model. The tumor types that offer the best comparative interest include lymphoma/leukemia, osteosarcoma, STS, melanoma, and mammary tumors. With the increase in new therapeutic agents (traditional chemotherapy, gene therapy, biologic agents, etc.), the companion animal model can provide useful populations to test new agents where efficacy and toxicity can be examined.
Journal of Veterinary Internal Medicine | 2009
C.F. Saba; S.D. Hafeman; David M. Vail; Douglas H. Thamm
BACKGROUND The combination of lomustine, L-asparaginase, and prednisone (LAP) is an effective rescue treatment for canine lymphoma (LSA). In a previous study, we reported that remission was typically lost around the time L-asparaginase was discontinued. HYPOTHESIS Use of L-asparaginase with each lomustine treatment will be well tolerated and efficacious as a rescue therapy for canine LSA. ANIMALS Forty-eight client-owned dogs with cytologically confirmed multicentric LSA whose disease had relapsed after a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol were included. METHODS Lomustine was administered orally at 3-week intervals, concurrently with subcutaneous or intramuscular L-asparaginase for a total of 5 doses or until disease progression. Prednisone was administered at a tapering dose for the duration of the protocol. RESULTS The overall response rate (ORR) for dogs treated with this protocol was 77%, with 65% achieving a complete response (CR). The median time to progression (TTP) was 70 days. Based on loose comparison, these findings are not significantly different from our previously reported historical control. The actual CCNU dosage administered did not affect response rate or remission duration. CONCLUSIONS/CLINICAL IMPORTANCE: These findings support previous data concluding that the LAP protocol is a viable rescue treatment option for dogs with LSA. However, results from this study suggest that continued use of L-asparaginase with each lomustine treatment does not significantly increase remission duration and toxicity appears greater.
Veterinary Clinics of North America-small Animal Practice | 1990
Gregory K. Ogilvie; David M. Vail
Cancer cachexia is a complex syndrome that results in involuntary weight loss, even in the face of adequate nutritional intake. The profound metabolic abnormalities associated with cancer cachexia affect a large percentage of animals with cancer even before any clinical signs are seen. This paraneoplastic syndrome results in alterations in carbohydrate, lipid, and protein metabolism that, if left untreated, decrease the animals quality of life and lead to a poor response to cancer therapy. An understanding of the metabolic abnormalities associated with cancer cachexia is of paramount importance to the practicing veterinarian to determine an accurate prognosis and to choose the optimal type of intravenous fluids and nutritional therapy for each patient. Although research identifying the optimal diet for cancer-bearing dogs and cats is still underway, some general principles apply. The first is that the patient should receive nutritional elements orally whenever possible. When oral feeding is not possible, nasogastric, gastrostomy, and jejunostomy tube feeding are viable options. When feeding by the gastrointestinal tract is not possible, parenteral feeding is a practical alternative.
Nature Biotechnology | 2006
Chand Khanna; Kerstin Lindblad-Toh; David M. Vail; Cheryl A. London; Philip J. Bergman; Lisa G. Barber; Matthew Breen; Barbara E. Kitchell; Elizabeth A. McNeil; Jaime F. Modiano; Steven Niemi; Kenine E. Comstock; Elaine A. Ostrander; Susan V. Westmoreland; Stephen J. Withrow
Seminars in Oncology | 2004
David M. Vail; Michael Amantea; Gail Colbern; Francis J. Martin; Ralf A. Hilger
International Journal of Radiation Oncology Biology Physics | 2004
Lisa J. Forrest; T Mackie; K Ruchala; Michelle Turek; Jeff Kapatoes; H. Jaradat; S Hui; John Balog; David M. Vail; Minesh P. Mehta
Journal of Veterinary Internal Medicine | 1990
David M. Vail; Gregory K. Ogilvie; Martin J. Fettman; Steven L. Wheeler
Veterinary Radiology & Ultrasound | 2010
Jessica Lawrence; Lisa J. Forrest; Michelle Turek; Paul E. Miller; T. Rockwell Mackie; H. Jaradat; David M. Vail; Richard R. Dubielzig; Rick Chappell; Minesh P. Mehta
Veterinary Radiology & Ultrasound | 2009
Jessica Lawrence; Matthew Vanderhoek; D Barbee; R Jeraj; Daniel B. Tumas; David M. Vail
Journal of Veterinary Internal Medicine | 1990
David M. Vail; Gregory K. Ogilvie; Steven L. Wheeler; Martin J. Fettman; Johnston Sd; Rebecca L. Hegstad